Now showing items 1-20 of 134

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      BACKGROUND:Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ...
    • Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice. 

      van Wamel, A; Sontum, PC; Healey, A; Kvåle, S; Bush, N; Bamber, J; de Lange Davies, C (2016-08)
      Acoustic cluster therapy (ACT) is a novel approach for ultrasound mediated, targeted drug delivery. In the current study, we have investigated ACT in combination with paclitaxel and Abraxane® for treatment of a subcutaneous ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      Background:Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
    • Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. 

      Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; Ritchie, AWS; Attard, G; Cross, W; Jones, RJ; Parker, CC; Russell, JM; Thalmann, GN; Schiavone, F; Cassoly, E; Matheson, D; Millman, R; Rentsch, CA; Barber, J; Gilson, C; Ibrahim, A; Logue, J; Lydon, A; Nikapota, AD; O'Sullivan, JM; Porfiri, E; Protheroe, A; Srihari, NN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-05)
      Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ...
    • Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. 

      Woods, BS; Sideris, E; Sydes, MR; Gannon, MR; Parmar, MKB; Alzouebi, M; Attard, G; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, PR; Cook, A; Cross, WR; Dearnaley, DP; Gale, J; Gibbs, S; Graham, JD; Hughes, R; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Peedell, C; Protheroe, A; Ritchie, AWS; Robinson, A; Russell, JM; Simms, MS; Srihari, NN; Srinivasan, R; Staffurth, JN; Sundar, S; Thalmann, GN; Tolan, S; Tran, ATH; Tsang, D; Wagstaff, J; James, ND; Sculpher, MJ (2018-12)
      BACKGROUND:Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic ...
    • Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. 

      Clarke, NW; Ali, A; Ingleby, FC; Hoyle, A; Amos, CL; Attard, G; Brawley, CD; Calvert, J; Chowdhury, S; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gilbert, D; Gillessen, S; Jones, RJ; Langley, RE; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Parker, CC; Ritchie, AWS; Rush, H; Russell, JM; Brown, J; Beesley, S; Birtle, A; Capaldi, L; Gale, J; Gibbs, S; Lydon, A; Nikapota, A; Omlin, A; O'Sullivan, JM; Parikh, O; Protheroe, A; Rudman, S; Srihari, NN; Simms, M; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A; Sydes, MR; Parmar, MKB; James, ND (2019-12)
      BACKGROUND:STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      BACKGROUND:Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ...
    • Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. 

      Brunner, C; Davies, NM; Martin, RM; Eeles, R; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, G; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Donovan, J; Hamdy, FC; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Pandha, H; PRACTICAL Consortium,; Zuccolo, L (2017-01)
      Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies. The effects of alcohol consumption on prostate cancer incidence and survival remain unclear, potentially ...
    • Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. 

      Moynihan, C; Bancroft, EK; Mitra, A; Ardern-Jones, A; Castro, E; Page, EC; Eeles, RA (2017-11)
      OBJECTIVE:Increased risk of prostate cancer (PCa) is observed in men with BRCA1/BRCA2 mutations. Sex and gender are key determinants of health and disease although unequal care exists between the sexes. Stereotypical male ...
    • Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. 

      Wu, L; Shu, X; Bao, J; Guo, X; Kote-Jarai, Z; Haiman, CA; Eeles, RA; Zheng, W; PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia (2019-09)
      Several blood protein biomarkers have been associated with prostate cancer risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein biomarkers ...
    • Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. 

      Winfield, JM; Poillucci, G; Blackledge, MD; Collins, DJ; Shah, V; Tunariu, N; Kaiser, MF; Messiou, C (2018-04)
      OBJECTIVES:The aim of this study was to identify apparent diffusion coefficient (ADC) values for typical haemangiomas in the spine and to compare them with active malignant focal deposits. METHODS:This was a retrospective ...
    • Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. 

      Payne, GS; Leach, MO (2006-09)
      Following advances in conformal radiotherapy, a key problem now facing radiation oncologists is target definition. While MRI and CT provide images of excellent spatial resolution, they do not always provide sufficient ...
    • Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. 

      Camacho, N; Van Loo, P; Edwards, S; Kay, JD; Matthews, L; Haase, K; Clark, J; Dennis, N; Thomas, S; Kremeyer, B; Zamora, J; Butler, AP; Gundem, G; Merson, S; Luxton, H; Hawkins, S; Ghori, M; Marsden, L; Lambert, A; Karaszi, K; Pelvender, G; Massie, CE; Kote-Jarai, Z; Raine, K; Jones, D; Howat, WJ; Hazell, S; Livni, N; Fisher, C; Ogden, C; Kumar, P; Thompson, A; Nicol, D; Mayer, E; Dudderidge, T; Yu, Y; Zhang, H; Shah, NC; Gnanapragasam, VJ; CRUK-ICGC Prostate Group; Isaacs, W; Visakorpi, T; Hamdy, F; Berney, D; Verrill, C; Warren, AY; Wedge, DC; Lynch, AG; Foster, CS; Lu, YJ; Bova, GS; Whitaker, HC; McDermott, U; Neal, DE; Eeles, R; Eeles, R; Cooper, CS; Brewer, DS (2017-09-25)
      A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively ...
    • Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. 

      Bonilla, C; Lewis, SJ; Rowlands, M-A; Gaunt, TR; Davey Smith, G; Gunnell, D; Palmer, T; Donovan, JL; Hamdy, FC; Neal, DE; Eeles, R; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, GG; Wiklund, F; Grönberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Pandha, H; PRACTICAL consortium; Lathrop, M; Martin, RM; Holly, JMP (2016-10)
      Circulating insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are associated with prostate cancer. Using genetic variants as instruments for IGF peptides, we investigated whether these associations are ...
    • Assessment of MLC tracking performance during hypofractionated prostate radiotherapy using real-time dose reconstruction. 

      Fast, MF; Kamerling, CP; Ziegenhein, P; Menten, MJ; Bedford, JL; Nill, S; Oelfke, U (2016-02)
      By adapting to the actual patient anatomy during treatment, tracked multi-leaf collimator (MLC) treatment deliveries offer an opportunity for margin reduction and healthy tissue sparing. This is assumed to be especially ...
    • Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 

      Schumacher, FR; Al Olama, AA; Berndt, SI; Benlloch, S; Ahmed, M; Saunders, EJ; Dadaev, T; Leongamornlert, D; Anokian, E; Cieza-Borrella, C; Goh, C; Brook, MN; Sheng, X; Fachal, L; Dennis, J; Tyrer, J; Muir, K; Lophatananon, A; Stevens, VL; Gapstur, SM; Carter, BD; Tangen, CM; Goodman, PJ; Thompson, IM; Batra, J; Chambers, S; Moya, L; Clements, J; Horvath, L; Tilley, W; Risbridger, GP; Gronberg, H; Aly, M; Nordström, T; Pharoah, P; Pashayan, N; Schleutker, J; Tammela, TLJ; Sipeky, C; Auvinen, A; Albanes, D; Weinstein, S; Wolk, A; Håkansson, N; West, CML; Dunning, AM; Burnet, N; Mucci, LA; Giovannucci, E; Andriole, GL; Cussenot, O; Cancel-Tassin, G; Koutros, S; Beane Freeman, LE; Sorensen, KD; Orntoft, TF; Borre, M; Maehle, L; Grindedal, EM; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Travis, RC; Key, TJ; Hamilton, RJ; Fleshner, NE; Finelli, A; Ingles, SA; Stern, MC; Rosenstein, BS; Kerns, SL; Ostrer, H; Lu, Y-J; Zhang, H-W; Feng, N; Mao, X; Guo, X; Wang, G; Sun, Z; Giles, GG; Southey, MC; MacInnis, RJ; FitzGerald, LM; Kibel, AS; Drake, BF; Vega, A; Gómez-Caamaño, A; Szulkin, R; Eklund, M; Kogevinas, M; Llorca, J; Castaño-Vinyals, G; Penney, KL; Stampfer, M; Park, JY; Sellers, TA; Lin, H-Y; Stanford, JL; Cybulski, C; Wokolorczyk, D; Lubinski, J; Ostrander, EA; Geybels, MS; Nordestgaard, BG; Nielsen, SF; Weischer, M; Bisbjerg, R; Røder, MA; Iversen, P; Brenner, H; Cuk, K; Holleczek, B; Maier, C; Luedeke, M; Schnoeller, T; Kim, J; Logothetis, CJ; John, EM; Teixeira, MR; Paulo, P; Cardoso, M; Neuhausen, SL; Steele, L; Ding, YC; De Ruyck, K; De Meerleer, G; Ost, P; Razack, A; Lim, J; Teo, S-H; Lin, DW; Newcomb, LF; Lessel, D; Gamulin, M; Kulis, T; Kaneva, R; Usmani, N; Singhal, S; Slavov, C; Mitev, V; Parliament, M; Claessens, F; Joniau, S; Van den Broeck, T; Larkin, S; Townsend, PA; Aukim-Hastie, C; Gago-Dominguez, M; Castelao, JE; Martinez, ME; Roobol, MJ; Jenster, G; van Schaik, RHN; Menegaux, F; Truong, T; Koudou, YA; Xu, J; Khaw, K-T; Cannon-Albright, L; Pandha, H; Michael, A; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Lindstrom, S; Turman, C; Ma, J; Hunter, DJ; Riboli, E; Siddiq, A; Canzian, F; Kolonel, LN; Le Marchand, L; Hoover, RN; Machiela, MJ; Cui, Z; Kraft, P; Amos, CI; Conti, DV; Easton, DF; Wiklund, F; Chanock, SJ; Henderson, BE; Kote-Jarai, Z; Haiman, CA; Eeles, RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium (2018-07)
      Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 ...
    • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 

      Khankari, NK; Shu, X-O; Wen, W; Kraft, P; Lindström, S; Peters, U; Schildkraut, J; Schumacher, F; Bofetta, P; Risch, A; Bickeböller, H; Amos, CI; Easton, D; Eeles, RA; Eeles, RA; Gruber, SB; Haiman, CA; Hunter, DJ; Chanock, SJ; Pierce, BL; Zheng, W; Colorectal Transdisciplinary Study (CORECT); Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE); Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE); Transdisciplinary Research in Cancer of the Lung (TRICL) (2016-09-06)
      BACKGROUND:Observational studies examining associations between adult height and risk of colorectal, prostate, and lung cancers have generated mixed results. We conducted meta-analyses using data from prospective cohort ...
    • Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. 

      Gusev, A; Shi, H; Kichaev, G; Pomerantz, M; Li, F; Long, HW; Ingles, SA; Kittles, RA; Strom, SS; Rybicki, BA; Nemesure, B; Isaacs, WB; Zheng, W; Pettaway, CA; Yeboah, ED; Tettey, Y; Biritwum, RB; Adjei, AA; Tay, E; Truelove, A; Niwa, S; Chokkalingam, AP; John, EM; Murphy, AB; Signorello, LB; Carpten, J; Leske, MC; Wu, S-Y; Hennis, AJM; Neslund-Dudas, C; Hsing, AW; Chu, L; Goodman, PJ; Klein, EA; Witte, JS; Casey, G; Kaggwa, S; Cook, MB; Stram, DO; Blot, WJ; Eeles, RA; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, GG; Southey, MC; Fitzgerald, LM; Gronberg, H; Wiklund, F; Aly, M; Henderson, BE; Schleutker, J; Wahlfors, T; Tammela, TLJ; Nordestgaard, BG; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, K-T; Stanford, JL; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Teerlink, C; Brenner, H; Dieffenbach, AK; Arndt, V; Park, JY; Sellers, TA; Lin, H-Y; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Spurdle, A; Clements, JA; Teixeira, MR; Pandha, H; Michael, A; Paulo, P; Maia, S; Kierzek, A; PRACTICAL consortium; Conti, DV; Albanes, D; Berg, C; Berndt, SI; Campa, D; Crawford, ED; Diver, WR; Gapstur, SM; Gaziano, JM; Giovannucci, E; Hoover, R; Hunter, DJ; Johansson, M; Kraft, P; Le Marchand, L; Lindström, S; Navarro, C; Overvad, K; Riboli, E; Siddiq, A; Stevens, VL; Trichopoulos, D; Vineis, P; Yeager, M; Trynka, G; Raychaudhuri, S; Schumacher, FR; Price, AL; Freedman, ML; Haiman, CA; Pasaniuc, B (2016-04-07)
      Although genome-wide association studies have identified over 100 risk loci that explain ∼33% of familial risk for prostate cancer (PrCa), their functional effects on risk remain largely unknown. Here we use genotype data ...
    • Blood lipids and prostate cancer: a Mendelian randomization analysis. 

      Bull, CJ; Bonilla, C; Holly, JMP; Perks, CM; Davies, N; Haycock, P; Yu, OHY; Richards, JB; Eeles, R; Easton, D; Kote-Jarai, Z; Amin Al Olama, A; Benlloch, S; Muir, K; Giles, GG; MacInnis, RJ; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Pashayan, N; Khaw, K-T; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Micheal, A; Pandha, H; Smith, GD; Lewis, SJ; Martin, RM; PRACTICAL consortium (2016-06)
      Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer ...
    • Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. 

      Denis-Bacelar, AM; Chittenden, SJ; McCready, VR; Divoli, A; Dearnaley, DP; O'Sullivan, JM; Johnson, B; Flux, GD (2018-04)
      OBJECTIVE:The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation ...